Providing some clinical pearls learned in the last week regarding patient education for ruxolitinib & alectinib. Then (11:50) we recap follow-up publications from Keynote-24 & the BRIGHT studies, before finishing up the week's journal scan with a discussion of the optimal dose of nivolumab + ipilimumab in melanoma and who may NOT benefit from palbociclib.
